Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

NAT2, Mouse, Clone: 3B5, Abnova™

Mouse monoclonal antibody raised against a partial recombinant NAT2.

Supplier:  Abnova Corporation H00000010M01

Catalog No. 89-016-003


Only null left
Add to Cart

Description

Description

This gene encodes an enzyme that functions to both activate and deactivate arylamine and hydrazine drugs and carcinogens. Polymorphisms in this gene are responsible for the N-acetylation polymorphism in which human populations segregate into rapid, intermediate, and slow acetylator phenotypes. Polymorphisms in this gene are also associated with higher incidences of cancer and drug toxicity. A second arylamine N-acetyltransferase gene (NAT1) is located near this gene (NAT2). [provided by RefSeq

Sequence: PPVNKYSTGMVHLLLQVTIDGRNYIVDAGSGSSSQMWQPLELISGKDQPQVPCIFCLTEERGIWYLDQIRREQYITNKEFLNSHLLPKKKHQKIYLFTLE
Specifications

Specifications

NAT2
Monoclonal
Unconjugated
PBS with no preservative; pH 7.4
BC015878
NAT2
NAT2 (AAH15878, 96 a.a. ∼ 195 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
100 μg
Primary
Human
Antibody
IgG2a κ
ELISA, Western Blot
3B5
Mouse monoclonal antibody raised against a partial recombinant NAT2.
NAT2
AAC2/PNAT
Mouse
Affinity chromatography
RUO
10
Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
Liquid
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.